_1736916783 20250115045303000 Editor editor.jddt@gmail.com Universal Journal of Pharmaceutical Research Universal Journal of Pharmaceutical Research Univ J Pharm Res 2456-8058 2831-5235 01 15 2025 Gameel Ahmed Mohammed Almohya https://orcid.org/0009-0001-2682-0272 Monya Abdullah Yahya El-Zine https://orcid.org/0000-0001-9033-3906 Hassan Abdulwahab Al-Shamahy https://orcid.org/0000-0001-6958-7012 Anowar Gasem Al-Madhaji https://orcid.org/0009-0009-3696-522X Rowa Mohammed Assayaghi https://orcid.org/0009-0003-2952-3120 Background and aims: Hepatitis B virus (HBV) screening for patients with newly diagnosed solid cancer is not standard practice in oncology, and authorities disagree on whether complete screening should be carried out. Additionally, research on the risk factors for HBV infection in this patient population may differ from that in the general population. Therefore, estimating the prevalence of HBV and risk factors for HBV infection in individuals with recently diagnosed solid cancer was the study's goal. Subjects and methods: Newly diagnosed cancer patients at the oncology center of Al-Jumhori Hospital in Sana'a, are included in this cross-sectional study. A regular questionnaire created specifically for this study was used to gather data, which included demographic information, risk factors, cancer type, and test findings. Using an ELISA assays for HB surface antigen and HB Core IgG anti-antibodies were conducted. Results: The study analyzed 300 cancer patients with HBV testing, with a mean age of 42.9 years and a sex distribution of 37.6% men and 62.4% women. The crude HBV prevalence was 5%, with females having a higher prevalence. The study found no significant association between age, rural residency, married status, blood transfusion frequency, or blood sources with HBV risk. No association was found between under treatment chemotherapy and HBV infection. Conclusions: This study examines the frequency of HBV infections in patients with solid tumors for the first time in Yemen. Our study found that the nationwide prevalence of HBV was higher in cancer patients than in the broad population.                    Peer Review History: Received 15 October 2024;   Reviewed 7 November; Accepted 21 December; Available online 15 January 2025 Academic Editor:  Dr. A.A. Mgbahurike, University of Port Harcourt, Nigeria, amaka_mgbahurike@yahoo.com Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 7.0/10 01 15 2025 http://creativecommons.org/licenses/by-nc/4.0 10.22270/ujpr.v9i6.1233 https://ujpronline.com/index.php/journal/article/view/1233 https://ujpronline.com/index.php/journal/article/download/1233/1758 https://ujpronline.com/index.php/journal/article/download/1233/1758 https://ujpronline.com/index.php/journal/article/download/1233/1771 https://ujpronline.com/index.php/journal/article/download/1233/1786